• Follow
  • Follow
  • Menu Item

Log in

Start free trial
  • Reports
    • Diagnostic Testing & Emerging Technologies
    • Lab Compliance Advisor
    • Laboratory Industry Report
    • National Lab Reporter
  • Articles
    • Diagnostic Testing and Emerging Technologies
      • DTC-dtet
      • Earnings-dtet
      • Emerging Tests-dtet
      • FDA-dtet
      • G2 Insider-dtet
    • Lab Compliance Advisor
      • Accreditation-lca
      • Brief Your CEO-lca
      • CLIA-lca
      • CMS-lca
      • Coding-lca
      • Compliance Corner-lca
      • Compliance Guidance-lca
      • Compliance Officers-lca
      • Compliance Perspectives-lca
      • Compliance Plans-lca
      • Compliance-lca
      • DOJ-lca
      • Employment-lca
      • Enforcement-lca
      • False Claims-lca
      • FDA-lca
    • Laboratory Industry Report
      • Capital-lir
      • CMS-lir
      • Deals-lir
      • Dx Pipeline-lir
      • Earnings-lir
      • Enforcement-lir
      • FDA-lir
      • Fee Schedules-lir
      • Funding-lir
    • National Lab Reporter
      • Guidelines at a Glance-nir
      • Health care reform-nir
      • HIPAA-nir
      • Labs in Court-nir
      • Legislation-nir
      • News-nir
      • OIG-nir
      • Reimbursement-nir
      • Safety-nir
  • News
  • Industry Perspectives
  • Webinars
  • Store

Diagnostic Testing and Emerging Technologies

LAB COMPLIANCE ADVISOR

LABORATORY INDUSTRY REPORT

NATIONAL LAB REPORTER

Preparing for or Considering Sale: The Anatomy of a Deal and Maximizing Your Opportunity

Preparing for or Considering Sale: The Anatomy of a Deal and Maximizing Your Opportunity

by G2 Intelligence Staff | May 31, 2023 | OLP, Webinars, webinars free

This panel will help laboratory owners make decisions now to be better positioned in the future for a potential sale.

Illegal Marketing Commissions Arrangements Cost Toxicology Lab $5.9 Million

Illegal Marketing Commissions Arrangements Cost Toxicology Lab $5.9 Million

by Glenn S. Demby | Apr 18, 2023 | News

Recent case shows that toxicology labs and drug testing remain a primary target for federal enforcement agencies.

How to Explain the Current State of EKRA to Your Lab Executives

How to Explain the Current State of EKRA to Your Lab Executives

by Glenn S. Demby | Feb 24, 2023 | Brief Your CEO-lca, Lab Compliance Advisor, Reimbursement-lca

How to explain the current state of EKRA to your lab executives.

This content is for Paid Members only.
Login Register
Lab Sales & Marketing Compliance: The Current State of EKRA

Lab Sales & Marketing Compliance: The Current State of EKRA

by Glenn S. Demby | Feb 9, 2023 | Enforcement-nir, National Lab Reporter

Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.

This content is for Paid Members only.
Login Register
Clinical Laboratory Enforcement Update

Clinical Laboratory Enforcement Update

by G2 Intelligence Staff | Jan 23, 2023 | Webinars, webinars free

Get an overview of trending areas of enforcement and steps labs and pathology practices can consider to protect their businesses.

« Older Entries

Log In


Join Now | Lost Password?

  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
Copyright © 2023 G2Intelligence.com